Summary of ASH 2016

| Jack Aiello

Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I attended early this morning focused on different transplant regimens. This was a large trials (750 newly diagnosed multiple myeloma patients) randomly divided into three arms. Arm 1, denote ACM, received one autologous stem cell transplant (ASCT), four cycles of Velcade-Revlimid-dexamethasone consolidation, then […]

Day 3: “Is that all there is?” –Peggy Lee

| Jack Aiello

Yes, today was the last full day of ASH but that’s not to say if wasn’t full of information with oral presentations packing the day from 7 a.m.–6 p.m. Highlights included these abstracts listed as follows (# abstract number): (#673) A 1200 pateint study showing benefit of an autologous stem cell transplant (ASCT) versus VMP […]

Day 2: Can anything compare with eliminating 24-hr urine collections?

| Jack Aiello

Today’s events began with 9:30 a.m. education program on 1) managing Newly Diagnosed High-Risk (HR) Multiple Myeloma patients 2) Sequencing treatments, and 3) the role of stem cell transplant (SCT) and maintenance. Dr Angela Dispenzieri spoke on the first topic, and she reminded the audience that “High-Risk” doesn’t just mean cytogenetic factors like del(17p), but […]

Day 1: mAb’s, CAR-T, and Checkpoints . . . oh my!

| Jack Aiello

Oh my indeed, what a very long but exciting day at ASH. It began with a 7:30 a.m. working breakfast of the IMF’s International Myeloma Working Group (IMWG) that consists of more than 200 myeloma experts from around the world (including 17 new members in 2016). One of their tasks is to write consensus guidelines and […]

The art of treatment decisions: Pre-ASH Day

| Jack Aiello

December 2nd is actually the day before ASH officially begins, often called “Symposium” day. However, my first session was a meeting of the IMF’s Global Myeloma Action Network (GMAN). This organization started four years ago and focuses on issues such as awareness, access, and education in other countries. We share best practices such as fundraising […]

What’s this event called ASH?

| Jack Aiello

Soon I’ll be off to San Diego, site of this year’s American Society of Hematology (ASH) conference. ASH is all about blood cancers (leukemia, lymphoma, multiple myeloma), and there are nearly 700 oral presentations and posters on myeloma alone. I’m so grateful to the International Myeloma Foundation (IMF) and their sponsors for sending me, and […]


Jack Aiello

Diagnosed with myeloma in 1995, Jack is strong proponent of patients participating in clinical trials so that, in the future, myeloma and other cancers will be known as curable diseases. He is a proud facilitator of the San Francisco Bay Area Myeloma Support Group.

Follow Jack on Twitter